Cargando…
Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study
OBJECTIVE: Cerebral vasospasm is the commonest cause for mortality and morbidity in patients following clipping of a ruptured aneurysm. Selective phosphodiesterase (PDE) inhibitor like sildenafil acts as a vasodilator. The objective of this study was to evaluate the safety and feasibility of oral si...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280003/ https://www.ncbi.nlm.nih.gov/pubmed/22347673 http://dx.doi.org/10.4103/2152-7806.92164 |
_version_ | 1782223768570036224 |
---|---|
author | Mukherjee, Kanchan K. Singh, Shrawan K. Khosla, Virender K. Mohindra, Sandeep Salunke, Pravin |
author_facet | Mukherjee, Kanchan K. Singh, Shrawan K. Khosla, Virender K. Mohindra, Sandeep Salunke, Pravin |
author_sort | Mukherjee, Kanchan K. |
collection | PubMed |
description | OBJECTIVE: Cerebral vasospasm is the commonest cause for mortality and morbidity in patients following clipping of a ruptured aneurysm. Selective phosphodiesterase (PDE) inhibitor like sildenafil acts as a vasodilator. The objective of this study was to evaluate the safety and feasibility of oral sildenafil citrate in patients with symptomatic refractory vasospasm. METHODS: A total of 832 patients with aneurysmal subarachnoid bleed were operated in 4 years. Two hundred and seventy-three patients had vasospasm. Of these, 72 patients had refractory cerebral vasospasm. Vasospasm was defined as refractory when institution of “HHH” failed to reverse the transcranial Doppler (TCD) values even after 24 hours. Computed tomography (CT) scan showed no infarct, hematoma, or hydrocephalus, and the serum electrolytes were within normal limits. They received 100–150 mg of sildenafil every 4 hours. Response was evaluated by 2-hourly TCD. RESULTS: Eight patients had sustained (TCD values normal for >48 hours) and four had temporary relief in vasospasm, as suggested. Four patients developed complications significant enough to terminate the therapy. CONCLUSIONS: Sildenafil citrate may be effective in patients with refractory symptomatic vasospasm. It calls upon the pharmacologists and scientists to discover newer supraselective PDE inhibitors, specific to PDE receptors in brain vessels. |
format | Online Article Text |
id | pubmed-3280003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-32800032012-02-16 Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study Mukherjee, Kanchan K. Singh, Shrawan K. Khosla, Virender K. Mohindra, Sandeep Salunke, Pravin Surg Neurol Int Original Article OBJECTIVE: Cerebral vasospasm is the commonest cause for mortality and morbidity in patients following clipping of a ruptured aneurysm. Selective phosphodiesterase (PDE) inhibitor like sildenafil acts as a vasodilator. The objective of this study was to evaluate the safety and feasibility of oral sildenafil citrate in patients with symptomatic refractory vasospasm. METHODS: A total of 832 patients with aneurysmal subarachnoid bleed were operated in 4 years. Two hundred and seventy-three patients had vasospasm. Of these, 72 patients had refractory cerebral vasospasm. Vasospasm was defined as refractory when institution of “HHH” failed to reverse the transcranial Doppler (TCD) values even after 24 hours. Computed tomography (CT) scan showed no infarct, hematoma, or hydrocephalus, and the serum electrolytes were within normal limits. They received 100–150 mg of sildenafil every 4 hours. Response was evaluated by 2-hourly TCD. RESULTS: Eight patients had sustained (TCD values normal for >48 hours) and four had temporary relief in vasospasm, as suggested. Four patients developed complications significant enough to terminate the therapy. CONCLUSIONS: Sildenafil citrate may be effective in patients with refractory symptomatic vasospasm. It calls upon the pharmacologists and scientists to discover newer supraselective PDE inhibitors, specific to PDE receptors in brain vessels. Medknow Publications & Media Pvt Ltd 2012-01-21 /pmc/articles/PMC3280003/ /pubmed/22347673 http://dx.doi.org/10.4103/2152-7806.92164 Text en Copyright: © 2012 Mukherjee KK. http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Article Mukherjee, Kanchan K. Singh, Shrawan K. Khosla, Virender K. Mohindra, Sandeep Salunke, Pravin Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study |
title | Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study |
title_full | Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study |
title_fullStr | Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study |
title_full_unstemmed | Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study |
title_short | Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study |
title_sort | safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: a feasibility study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280003/ https://www.ncbi.nlm.nih.gov/pubmed/22347673 http://dx.doi.org/10.4103/2152-7806.92164 |
work_keys_str_mv | AT mukherjeekanchank safetyandefficacyofsildenafilcitrateinreversalofcerebralvasospasmafeasibilitystudy AT singhshrawank safetyandefficacyofsildenafilcitrateinreversalofcerebralvasospasmafeasibilitystudy AT khoslavirenderk safetyandefficacyofsildenafilcitrateinreversalofcerebralvasospasmafeasibilitystudy AT mohindrasandeep safetyandefficacyofsildenafilcitrateinreversalofcerebralvasospasmafeasibilitystudy AT salunkepravin safetyandefficacyofsildenafilcitrateinreversalofcerebralvasospasmafeasibilitystudy |